Heberprot-P: The challenge of prevention still remains


HAVANA – Inscriptions in nearly 30 countries across all latitudes and a group of 290,000 patients seen since its launch a decade ago are some of the achievements of Heberprot-P, the only drug in the world to treat ulcers worldwide. diabetic foot.

In fact, the disease, considered a global pandemic, has a high incidence on the island, with numbers approaching the millions of people who suffer from it.

But the research associated with this drug and the pharmacovigilance studies do not stop. Its developers, from Center for Genetic Engineering and Biotechnology (CIGB) now seek that the injectable, whose active ingredient is the epidermal growth factor, is less invasive for the patient.

Administered directly into the ulcerated tissues, it infiltrates the needle lesions, to a depth of 0.1 centimeter.

Such procedure is sometimes painful for the patient, especially at the edges and bottom of the lesions at the time of application, said Cuban scientist Jorge Berlanga, leader of the study.

The CIGB formulations group works on the search for a new pharmaceutical form, the so-called intelligent formulations that are characterized by having a sustained release pattern over time.

The goal is to reduce the number of treatments, with this hypothesis we work.

"This way, if some of the alternatives are reached, it will be a step forward, but also a great challenge. We must see how the cell responds to the presence of sustained release, as the receiver changes, this is a challenge ahead" Berlanga.

But having a single drug available to patients to treat this medical problem is not the solution. Scientists argue that prevention work is needed, especially in a nation whose predictions indicate that by the middle of the century adults over 60 years of age are one-third of the population.

In addition to being a social problem, from an economic point of view it is necessary to interrupt the progression of the disease from the primary care, because in the opinion of the specialists, many lesions can be treated and closed in the initial stages, where there is low complexity.

In this way, direct and indirect costs in health systems are reduced. This helps the family economy and also the country's economy, they explain.

At the same time, for several years, the Cuban anthology community has focused on applying better epidemiological strategies to at least deal with the possible diseases that are to come, said Alejandro Hernández, director of the Institute of Angiology and Surgery Vascular. objective of AngioCaribe 2016.

Developing preventive programs at the primary care levels, not to reach difficult situations in patients, is one of the premises, he said.

At that time, the entity presented the study Magnitude and transcendence of peripheral vascular diseases in Cuba, to uncover the prevalence of these diseases in the island.

From its results, it was discovered that peripheral vascular diseases Cuba among the top 10 causes of death (seventh place), with a gross mortality rate of 25.5 per 100,000 inhabitants, hence the need to achieve coherent intervention strategies, as statistics say, in the world, in the case of diseases peripheral artery disease, two-thirds of the people who suffer from them are asymptomatic and underdiagnosed.

In these circumstances, the scientific institutions mentioned above organize the International Diabetes Control Congress and its most serious complications, a consultation that brings together researchers from all walks of life and a great representation of the United States.

In fact, the American nation is interested in having this drug available to them. Earlier this year, Cuban company Heber Biotec of CIGB and American company Mercurio Biotec agreed to join efforts to bring Heberprot-P therapy to patients with diabetic foot ulcers in the north of the country once approved by the Drug Administration and That country's food (the FDA, for its acronym in English).

Scientists from the United States and colleagues from other parts of the world will learn about the latest advances in the treatment of this disease in five symposia, among them. Endocrinology of diabetes, the state of the art in the treatment of wound healing, as well as the implementation of health programs for the integral care of people with diabetes.

These add cardiovascular problems associated with diabetes and implementation of health programs for the integral care of people with diabetes.


Source link